knowledge -WSS

knowledge

author：entertainment 2025-09-10 05:00:38 - browse：6566

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： The haunting brain science of long Covid

focus

WSS

Former reverend arrested for allegedly killing 8

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Biogen says it will cut costs by $700 million, slash 1,000 jobs

In the gardens at Boston Children's Hospital, families find sanctuary

The battle over 'scope creep' and who gets to be called 'doctor'

STAT Report: Patient voices and perspectives

hotspot

knowledge

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Dems pitch expanding Medicare power to negotiate drug prices

Hollywood unions extend contract negotiations for actors

Dems pitch expanding Medicare power to negotiate drug prices

Affirmative action in medical school literally saved lives

Millions may soon lose Medicaid when they don't have to

Psychedelics group wrestles with new pharma identity

Why patients can’t get everything they want on drug pricing

Anesthesiologist group: stop taking Ozempic before surgery

New lawsuit accuses health insurer Cigna of denying claims in bulk

leisure time

Biden administration plans revamp of organ transplant system

Eli Lilly’s Mounjaro succeeds in second weight

Bispecific antibodies are next new thing in cancer immunotherapy

What causes rare myocarditis in young men after Covid vaccines?

Will the FTC rein in IQVIA's health data empire?

'Investigate these claims': UFO transparency at center of House hearing

focus

leisure time

focus

entertainment